A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/12/2002	US6479519 Inhibitors of cell adhesion; treatment of asthma or inflammatory bowel disease
11/12/2002	US6479518 Zwitterionic tachykinin receptor antagonists
11/12/2002	US6479517 Treatment of post-menopausal syndrome: osteoporosis, cardiovascular effects such as hyperlipidemia, and estrogen-dependent cancer, particularly breast and uterine cancer
11/12/2002	US6479516 4-arylpiperidine derivatives for the treatment of pruritus
11/12/2002	US6479514 Quinoline-aminomethyl-pyridyl derivatives with anti-helicobacter activity
11/12/2002	US6479513 Anticancer compound and enantiomer separation method useful for synthesizing said compound
11/12/2002	US6479512 Tyrosine kinase inhibitors
11/12/2002	US6479510 N-((2s,3r)-2-methyl-1-azabicyclo(2.2.2)oct-3-yl)-4-(4-hydroxyp henoxy)- benzamide for example; treating diseases of the alpha-7-nicotinic acetylcholine receptor i.e. schizophrenia, or psychosis
11/12/2002	US6479509 Method of promoting smoking cessation
11/12/2002	US6479508 Viral polymerase inhibitors
11/12/2002	US6479507 Modulation of these inflammatory cytokines is considered one of the most effective strategies to block chronic inflammation and have positive therapeutic outcomes
11/12/2002	US6479506 Triazolo-pyridine derivatives as ligands for GABA receptors
11/12/2002	US6479505 6-arylphenanthridines with PDE-IV inhibiting activity
11/12/2002	US6479504 Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
11/12/2002	US6479503 Cycloalkano-indole and -azaindole derivatives
11/12/2002	US6479502 Hydroxamic acid derivatives as proteinase inhibitors
11/12/2002	US6479501 Cognition activators; antidepressants
11/12/2002	US6479500 Alleviating side effects caused by use of an anti-tumor agent comprising administering 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1h,3h)-pyrimidin edione
11/12/2002	US6479497 Compounds having a selective effect at a subgroup of 5-hydroxytryptamine receptors, designated the h5-ht1b receptor
11/12/2002	US6479496 Treating a human patient suffering from variant and exercise-induced angina by administering a sustained release pharmaceutical dosage form including at least 50% by weight ranolazine in no more than two tablets per dose
11/12/2002	US6479494 Arylalkanoyl pyridazines
11/12/2002	US6479493 Inhibiting phosphodiesterase 2 in the diseased tissue, without substantially inhibiting cyclooxygenases i and ii, thereby causing macrophage apoptosis
11/12/2002	US6479492 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/12/2002	US6479490 Treatment of diseases characterized by excess th2 cytokines and/ or an excess ige production.
11/12/2002	US6479488 Good in vitro affinity for the strychnine insensitive glycine binding site associated with the nmda receptor complex but also good in vivo activity when administered systemically
11/12/2002	US6479487 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
11/12/2002	US6479484 Substituted 2-aminoacetamides and the discovery that these compounds act as blockers of sodium channels; pain relievers, treatment of arrythmia, local anesthetics
11/12/2002	US6479483 3,4,6-substituted pyridine derivatives useful for treating depression and pain, resulting from inflammatory conditions, such as migraine, rheumatoid arthritis, asthma and inflamatory bowel disease; nk1 receptor antagonist
11/12/2002	US6479481 Administering an effective dose of a cns tumor-inhibiting methylol transfer agent such as: taurolidine, taurultam or a mixture thereof.
11/12/2002	US6479480 1h-indole derivatives bearing an optionally substituted phenyl moiety at the 2-position of the indole ring system and a methylene-linked heterocyclic moiety at the 3-position of the indole ring system; schizophrenia treatment
11/12/2002	US6479477 Substituted porphyrins
11/12/2002	US6479476 Treating menopausal symptoms and osteoporosis in female warm-blooded animals
11/12/2002	US6479475 Oral contraceptive
11/12/2002	US6479474 Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
11/12/2002	US6479473 Long-acting antimicrobials
11/12/2002	US6479472 Methods of using therapeutic phospholipid derivatives
11/12/2002	US6479471 Novel phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives that inhibit n-acetylated .alpha.-linked acidic dipeptidase (naaladase) enzyme activity to treat prostate diseases
11/12/2002	US6479470 Naag and naaladase have been implicated in several pathological conditions relating to glutamate abnormalities and neurotoxicity
11/12/2002	US6479469 N-acylated-2-glucosamine derivatives for treating osteoarthritis/inflammatory arthritis, and enhancing cartilage formulation, chondrocyte cell proliferation and glycosaminoglycan production
11/12/2002	US6479468 Oxidized and reduced polysaccharide exhibits a longer vascular half-life than unmodified starch, slower degradation by amylase than unmodified starch, and/or slower the smaller the allergenicity
11/12/2002	US6479466 A hydroxylated stilbene that promotes dna synthesis in a virally-targeted cell such as resveratrol; a nucleoside analogue having antiviral activity such as dideoxyinosine
11/12/2002	US6479463 Used to treat an infection, an infestation, a neoplasm, or an autoimmune disease or to modulate aspects of the immune system, including modulation of th1 and th2
11/12/2002	US6479461 Use of alkylmonoglucosides as molecular vectors
11/12/2002	US6479460 Pseudopeptidic osteogenic growth polypeptide
11/12/2002	US6479458 Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
11/12/2002	US6479283 Stimulation, culture and preservation of pancreatic cells
11/12/2002	US6479265 Catalytic antibodies which hydrolyze primary amides and methods for eliciting and use of such antibodies
11/12/2002	US6479245 Monoclonal antibody which is specific for activated coagulation factor VII, and its use
11/12/2002	US6479078 Substantially crystalline form of melagatran
11/12/2002	US6479076 Nicotine delivery compositions
11/12/2002	US6479075 Pharmaceutical formulations for acid labile substances
11/12/2002	US6479070 Compositions containing pinolenic acid and its use as a health component
11/12/2002	US6479067 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
11/12/2002	US6479063 Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
11/12/2002	US6479057 Cosmetic compositions containing inorganic-organic hybrid prepolymers and methods of treating hair, skin or nails using same
11/12/2002	US6479039 Antimicrobial artificial nail composition and methods for preparing and using same
11/12/2002	US6479035 Pharmaceutical formulation of fluticasone propionate
11/12/2002	US6479033 Antitumor cystostatic and contrast agent
11/12/2002	US6478796 Spin distraction implant and method
11/12/2002	CA2324959C Phthalimido compounds as intermediates for producing substance p receptor antagonists
11/12/2002	CA2266478C Polymerizable biodegradable polymers including carbonate or dioxanone linkages
11/12/2002	CA2249458C Antipsoriatic compositions, method of making, and method of using
11/12/2002	CA2246839C Pharmaceutical compositions containing ampa receptor antagonists for treating dyskineslas associated with dopamine agonist therapy
11/12/2002	CA2244253C Method for preventing and treating peripheral neuropathy by administering selegiline
11/12/2002	CA2169718C The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases
11/12/2002	CA2169635C Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
11/12/2002	CA2144294C (pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments
11/12/2002	CA2110162C Pharmaceutical compositions containing 4-substituted imidazoles to be administered transdermally
11/12/2002	CA2103242C Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use
11/12/2002	CA2101227C Chlorophyll and bacteriochlorophyll derivatives and pharmaceutical compositions containing them
11/12/2002	CA2099591C 7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3- carboxylic acid compounds useful as antibacterial agents
11/12/2002	CA2092435C Uracil reductase inactivators
11/12/2002	CA2088917C Therapeutic ribozyme compositions
11/12/2002	CA2088289C Pharmaceutically active composition extracted from tanacetum parthenium, process for its extraction, and pharmaceutical composition containing same
11/12/2002	CA2079581C Crystalline etoposide 4'-phosphate diethanolate
11/12/2002	CA2077102C Antibiotic ge 2270 factor c2a
11/12/2002	CA2076498C Indole derivatives and their use
11/12/2002	CA2071518C Oral composition for the treatment of inflammatory bowel diseases
11/12/2002	CA2068083C Anti-bacterial compound
11/12/2002	CA2059558C Use of calcium antagonists for treating scars
11/12/2002	CA2055948C Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria
11/12/2002	CA2049668C Bioerodible implants
11/12/2002	CA2018564C 4,5,5a,6-tetrahydro-3h-isoxazolo¬5,4,3-kl\|acridines derivatives, a process for their preparation and their use as medicaments
11/11/2002	CA2385692A1 Thiazole derivatives
11/11/2002	CA2385510A1 Use of hydroxyflavanones for masking bitter taste
11/11/2002	CA2347879A1 Substituted dicinnamoylquinides and their use in augmentation of adenosine function
11/09/2002	CA2385744A1 Decalactones, method for making, and pharmaceuticals therefrom
11/09/2002	CA2385412A1 Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
11/08/2002	WO2001082942A1 Compositions and methods for treatment of multiple myeloma
11/08/2002	CA2425954A1 Compositions and methods for treatment of multiple myeloma
11/07/2002	WO2002088664A2 Control of compactability through crystallization
11/07/2002	WO2002088374A1 Process for producing isomaltose and use thereof
11/07/2002	WO2002088366A1 Von willebrand factor (vwf)-cleaving enzyme
11/07/2002	WO2002088323A2 Gene delivery compounds
11/07/2002	WO2002088286A1 Sterol compositions, fat compositions containing the same and foods
11/07/2002	WO2002088167A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002	WO2002088159A1 Pharmaceutically active uridine esters
11/07/2002	WO2002088147A1 Sulfate of cephem compound
11/07/2002	WO2002088146A2 ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H-[1,4]DIOXINO[2,3-e]INDOLE
11/07/2002	WO2002088144A2 ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-f]QUINOXALINE

1 ... 5654 5655 5656 5657 5658 5659 5660 5661 5662 5663 5664 5665 5666 5667 5668 5669 5670 5671 5672 5673 5674 ... 7860